A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients.
Alvarez
R D
RD
Gene Therapy Program, Wallace Tumor Institute, Birmingham, AL 35233-7333, USA.
Curiel
D T
DT
D000256:Adenoviridae / Q000235:genetics; D000998:Antiviral Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007275:Injections, Intravenous; D010051:Ovarian Neoplasms / Q000628:therapy*; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics*; D016896:Treatment Outcome
D000998:Antiviral Agents; D013937:Thymidine Kinase; D015774:Ganciclovir